Enas H Mahmoud

Enas H Mahmoud

Auto-generated profile, based on publicly available information

Enas H Mahmoud

Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2016 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
EMEnas H Mahmoud
Enas H Mahmoud
AFAmal Fawzy
Amal Fawzy
OAOmar K Ahmad
Omar K Ahmad
AAAmr M Ali
Amr M Ali
Plasma Circulating Cell-free Nuclear and Mitochondrial DNA as Potential Biomarkers in the Peripheral Blood of Breast Cancer Patients Breast cancer;ccf nuclear DNA;ccf mitochondrial DNA;diagnostic markers; Background: In Egypt, breast cancer is estimated to be the most common cancer among females. It is also a leading cause of cancer-related mortality. Use of circulating cell-free DNA (ccf-DNA) as non-invasive biomarkers is a promising tool for diagnosis and follow-up of breast cancer (BC) patients. Objective: To assess the role of circulating cell free DNA (nuclear and mitochondrial) in diagnosing BC. Materials and Methods: Multiplex real time PCR was used to detect the level of ccf nuclear and mitochondrial DNA in the peripheral blood of 50 breast cancer patients together with 30 patients with benign lesions and 20 healthy controls. Laboratory investigations, histopathological staging and receptor studies were carried out for the cancer group. Receiver operating characteristic curves were used to evaluate the performance of ccf-nDNA and mtDNA. Results: The levels of both nDNA and mtDNA in the cancer group were significantly higher in comparison to the benign and the healthy control group. There was a statistically significant association between nDNA and mtDNA levels and well established prognostic parameters; namely, histological grade, tumour stage, lymph node status andhormonal receptor status. Conclusions: Our data suggests that nuclear and mitochondrial ccf-DNA may be used as non-invasive biomarkers in BC.

17 August 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
NMNehad A. Mossad
Nehad A. Mossad
EMEnas H. Mahmoud
Enas H. Mahmoud
EOEnas A. Osman
Enas A. Osman
SMSherif H. Mahmoud
Sherif H. Mahmoud
HSHend I. Shousha
Hend I. Shousha

1 January 2016 in Annals of Pediatric Cardiology
Verified
Journal Article
Open access
PDF file
MEMortada H El-Shabrawi
Mortada H El-Shabrawi
AFAya M Fattouh
Aya M Fattouh
EMEnas H Mahmoud
Enas H Mahmoud
WAWafaaO Ahmed
WafaaO Ahmed
Background: Cirrhotic cardiomyopathy (CCM) is described as the presence of cardiac dysfunction in cirrhotic patients. In children with chronic liver disease, CCM has been very rarely investigated. The Aim of the Study: Is to evaluate the cardiac function of cirrhotic children to identify those with CCM. Patients and Methods: Fifty-two cirrhotic patients and 53 age and sex matched controls were assessed using serum brain-type natriuretic peptide (BNP), conventional echocardiography, and tissue Doppler imaging. Results: Patients' mean ages were 7.66 ± 4.16 years (vs. 6.88 ± 3.04 years for the controls). The study included 27 males and 25 females (28 and 25 respectively for the controls). Patients had larger left atrium and right ventricle (RV) (P value 0.05) and increased LV posterior wall thickness than controls (P value 0.04). They had higher late atrial diastolic filling velocity (A) of tricuspid valve (TV) inflow (0.59 ± 0.17 vs. 0.5 ± 0.1 m/s P < 0.001) and lower ratios between the early diastolic filling velocity (E) and A wave velocity (E/A) of both mitral valve and TV inflow (1.7 ± 0.35 vs. 1.87 ± 0.34 and 1.3 ± 0.3 vs. 1.5 ± 0.3 P < 0.005 and 0.0008, respectively). Patients had significantly longer isovolumic relaxation time of LV (45.5 ± 11.1 vs. 40.5 ± 7.7 ms P0.008), higher late diastolic peak myocardial velocity (AͲ) (11.8 ± 3.6 vs. 9.5 ± 2.7 ms P 0.0003) and systolic velocity (SͲ) of the RV (14.5 ± 2.7 vs. 13.2 ± 2.9, P 0.01) and significantly higher myocardial performance index of both LV and RV (P 0.001 and 0.01). BNP levels were significantly higher in cases than controls (5.25 ng/l vs. 3.75 ng/l, P < 0.04) and was correlated with the E wave velocity of the TV (r 0.004) and the E/EͲ ratio of the RV (r 0.001). None of the clinical or laboratory data were correlated with the BNP level. Conclusion: Cirrhotic children have cardiac dysfunction mainly in the form of diastolic dysfunction. There is a need that CCM be more accurately described in children.

1 June 2017
Verified
Journal Article
Open access
PDF file
LMLamia A Mansour
Lamia A Mansour
MRMaissa El Raziky
Maissa El Raziky
AMAmal A Mohamed
Amal A Mohamed
EMEnas H Mahmoud
Enas H Mahmoud
SHSherif Hamdy
Sherif Hamdy
ESEnas H El Sayed
Enas H El Sayed
Background: Detection of circulating DNA can be applied for the diagnosis of many malignant neoplasms, including the hepatocellular carcinoma (HCC). The molecular pathogenesis of HCC is complex, involving different genetic and epigenetic alterations, chromosomal aberrations, gene mutations and altered molecular pathways. RASSF1A is a well-established tumor suppressor gene which suffers frequent inactivation due to promoter hypermethylation of CPG islands in multiple tumors including HCC, resulting in the reduction or loss of gene expression. Objective: To examine the role of circulating RASSF1A as a non-invasive diagnostic marker for HCC. Participant and Methods: A total of 45 HCC patients with a background of HCV infection, 40 cases of HCV infection without tumours and 40 apparently healthy controls were subjected to full history taking, clinical examination, routine laboratory investigations, assessment of serum AFP and detection of circulating hypermethylated RASSF1A gene by methylation-sensitive restriction enzyme digestion and real-time PCR. Results: The level of hypermethylated RASSF1A was significantly elevated in the HCC group as compared to the HCV and control groups (p=0.001 for both). Copy number in serum was associated with increased tumor size (p value <0.001). On the other hand, no significant correlation was observed between RASSF1A and AFP (p=0.5). Using ROC curve analysis, the best cut-off for circulating serum RASSF1A to differentiate the HCC group was 8 copies/μl. Conclusion: The presence of hypermethylated RASSF1A in serum may be a useful and informative biomarker for HCC diagnosis and might be introduced as a screening method for populations at risk of HCC development.

11 March 2011 in Comparative Clinical Pathology
Verified
Journal Article
Closed access
PDF file
EHEnas Hamdy
Enas Hamdy
RAReham A. Aleem Afify
Reham A. Aleem Afify
AKAbeer Kamal
Abeer Kamal
DADoaa Abass
Doaa Abass
MMManal Mahmoud
Manal Mahmoud